Prestige And Pharmapark Add Bevacizumab To Russia Collaboration

Commercialization Agreement Signed In 2019 Over Herceptin Biosimilar

 
• By Dean Rudge

Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.

Meeting
The Singapore-based biotech’s HD204 bevacizumab biosimilar is currently undergoing a Phase III clinical study • Source: Shutterstock

More from Biosimilars

More from Products